NVS
NOVARTIS AG
NYSE: NVS · Basel, V8 · Healthcare
$147.97-3.02 (-2.00%)Closed
Market Cap$282.35B
Cash—most recent
Runway—
P/E (TTM)—
52-Wk Range$101.89 – $163.64
Avg Volume1.8M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$147.97+66.3%
Pipeline

Drug candidates sponsored by NOVARTIS · ClinicalTrials.gov

82 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Enteric-Coated Mycophenolate Sodium (EC-MPS)
De Novo Kidney Transplantation
Completed
2005-07past
1
Phase 4amlodipine/benazepril
Albuminuria
Completed
2005-10past
1
Phase 4Everolimus
Renal Transplantation
Completed
2006-03past
1
Phase 4carbidopa, levodopa, entacapone
Parkinson's Disease
Completed
2006-06past
1
Phase 4Zoledronic acid
Prostate Cancer+1 more
Completed
2008-03past
2
Phase 4Mycophenolate sodium
Kidney Transplantation
Completed
2008-12past
1
Phase 4Xolair
Asthma
Completed
2009-01past
1
Phase 4Enteric-coated Mycophenolate Acid (EC-MPA)
Renal Transplantation
Terminated
2009-03past
1
Phase 4telbivudine/LDT600
Compensated Chronic Hepatitis B
Completed
2011-04past
1
Phase 4Unnamed
Tick Borne Encephalitis (TBE)
Completed
2011-05past
1
Phase 4vildagliptin and metformin (combination)
Type 2 Diabetes+1 more
Completed
2016-02-22past
1
Phase 4Placebo of vildagliptin
Type 2 Diabetes Mellitus
Completed
2019-04-04past
1
Phase 4Ranibizumab
Neovascular Age-related Macular Degeneration+1 more
Completed
2022-04-21past
2
Phase 4Fingolimod
Relapsing Remitting Multiple Sclerosis+1 more
Active, not recruiting
2026-03-25past
2
Phase 4Ofatumumab
Relapsing Multiple Sclerosis+2 more
Active, not recruiting
2027-04-13
3
Phase 3Enteric-Coated Mycophenolate Sodium
Prevention of Acute Rejection After Kidney Transplantation
Completed
2005-06past
1
Phase 3aliskiren
Hypertension
Completed
2006-03past
2
Phase 3valsartan
Hypertension
Completed
2006-03past
1
Phase 3valsartan + amlodipine
Hypertension
Completed
2007-08past
2
Phase 3Adjuvanted trivalent inactivated subunit influenza vaccine
Influenza, Human
Completed
2010-04past
1
Phase 3Lapatinib (GW572016) oral tablets
Neoplasms, Breast
Completed
2010-06-18past
1
Phase 3AIN457
Uveitis
Terminated
2011-01past
1
Phase 2TRI476
Partial Onset Seizures
Completed
2012-10past
1
Phase 3secukinumab 150 mg
Moderate to Severe Plaque-type Psoriasis
Completed
2013-04past
1
Phase 3Tacrolimus (reduced tacrolimus)
Liver Transplant Recipient
Completed
2013-05-03past
1
Phase 3Dabrafenib
Melanoma
Completed
2013-08-26past
1
Phase 3ACZ885
Cryopyrin-associated Periodic Syndromes+3 more
Completed
2014-11past
1
Phase 3Secukinumab 300 mg
Chronic Scalp Psoriasis
Completed
2015-12-07past
1
Phase 3Lapatinib
Neoplasms, Breast
Completed
2016-03-11past
1
Phase 3QVA149
Chronic Obstructive Pulmonary Disease
Completed
2016-09-12past
1
Phase 3QMF149
Asthma
Completed
2018-07-19past
1
Phase 3Placebo 2 mL auto-injector
Plaque Psoriasis
Completed
2019-11-19past
1
Phase 3Ribociclib
Advanced Metastatic Breast Cancer+5 more
Completed
2021-06-11past
5
Phase 3Secukinumab
Axial Psoratic Arthritis+1 more
Completed
2021-12-23past
2
Phase 3LCZ696
Hypertension+2 more
Completed
2022-05-16past
4
Phase 3Ligelizumab
Chronic Spontaneous Urticaria
Terminated
2022-09-01past
1
Phase 3Capmatinib
Carcinoma, Non-Small-Cell Lung
Terminated
2022-12-27past
1
Phase 3LOU064
Chronic Spontaneous Urticaria
Completed
2024-04-25past
1
Phase 3ianalumab
Systemic Lupus Erythematosus
Active, not recruiting
2027-04-12
1
Phase 3LNP023
Primary IgA Nephropathy+1 more
Recruiting
2032-10-25
2
Phase 3Remibrutinib
Indication of the Parent Protocol
Not yet recruiting
2033-01-30
1
Phase 3Vildagliptin
Diabetes Mellitus, Type 2
Completed—2
Phase 2epothilone b
Breast Neoplasms
Completed
2003-11past
1
Phase 2MenACWY-CRM conjugate vaccine, adjuvanted
Prevention of Meningococcal Disease
Completed
2006-03past
1
Phase 2Letrozole
Recurrent and Metastatic Endometrial Cancer
Completed
2006-06past
1
Phase 2Indacaterol
Asthma
Completed
2007-11past
1
Phase 2Panobinostat
Classical Hodgkin's Lymphoma
Completed
2013-08-12past
1
Phase 2AUY922
Non-small-cell Lung Cancer
Completed
2014-08past
1
Phase 2LEE011 (ribociclib)
Early Breast Cancer
Terminated
2014-09past
1
Phase 2imatinib mesylate
Gastrointestinal Stromal Tumor (GIST)
Completed
2016-12-20past
1
Phase 2bimagrumab
Sarcopenia
Completed
2018-06-26past
1
Phase 2LYS228
Intra-abdominal Infections
Terminated
2018-09-24past
1
Phase 2Unnamed
Chronic Plaque-type Psoriasis
Completed
2020-01-28past
1
Phase 2BAF312 solution
Hemorrhagic Stroke+1 more
Completed
2020-05-13past
1
Phase 2Eltrombopag
Poor Graft Function
Terminated
2020-11-03past
1
Phase 2LOU064 Arm 1
Chronic Spontaneous Urticaria
Completed
2021-01-14past
1
Phase 2ECF843
Dry Eye
Completed
2021-05-13past
1
Phase 2Inclisiran
Atherosclerotic Cardiovascular Disease+3 more
Completed
2021-12-17past
1
Phase 2Alpelisib
PIK3CA-related Overgrowth Spectrum (PROS)
Active, not recruiting
2024-03-20past
1
Phase 2Atrasentan
IgA Nephropathy+5 more
Active, not recruiting
2024-07-02past
1
Phase 2NIS793
Metastatic Colorectal Cancer
Terminated
2025-01-20past
1
Phase 2Nilotinib
Chronic Myeloid Leukemia+1 more
Completed
2025-10-15past
2
Phase 2GXV813
Schizophrenia
Recruiting
2027-04-27
1
Phase 1AAA602
Prostate Cancer
Withdrawn
2030-03-31
1
Phase 1Patupilone
Advanced Malignancies
Completed
2008-02past
1
Phase 1Monovalent GBS-CRM glycoconjugate vaccine
Invasive Group B Streptococcus (GBS) Disease
Completed
2009-04past
1
Phase 1LBH589
Cancer+1 more
Completed
2009-11past
1
Phase 1Buparlisib
Renal Impairment
Completed
2015-03past
1
Phase 1HDM201
Advanced Solid and Hematological TP53wt Tumors
Completed
2017-06-20past
1
Phase 1ABL001
Hepatic Impairment
Completed
2017-07-20past
1
Phase 1Pazopanib
Carcinoma, Renal Cell
Completed
2019-02-27past
1
Phase 1Licarbazepine
Healthy
Completed—1
N/AIndacaterol (Onbrez®) /QAB149
Chronic Obstructive Pulmonary Disease
Completed
2013-12past
1
N/ATasigna
All Indications for Glivec/Gleevec and Tasigna
Completed
2015-03past
1
N/AUnnamed
Invasive Group B Streptococcus Disease
Withdrawn
2015-08past
1
N/AUnnamed
Chronic Heart Failure (CHF)
Completed
2018-03-23past
1
N/AUnnamed
Age-related Macular Degeneration (AMD)
Completed
2020-09-25past
1
N/AUnnamed
Diabetic Macular Edema
Completed
2024-06-29past
1
N/AUnnamed
Leukemia, Myeloid, Chronic-Phase
Not yet recruiting
2026-09-19
1
N/AUnnamed
Non-Small-Cell Lung Carcinoma
Recruiting
2026-10-31
1
N/ATerbinafine hydrochloride
Candidiasis, Oral+1 more
Completed—1
N/AMidostaurin
Acute Myeloid Leukemia (AML) With+1 more
No Longer Available—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for NVS. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.